Alvotech launches first biosimilar of J&J’s Stelara in Europe
- Alvotech (NASDAQ:ALVO) and STADA have launched the first biosimilar of Johnson & Johnson’s (NYSE:JNJ) IL-12 and IL-23 antagonist Stelara, known as Uzpruvo.
- Uzpruvo is indicated for Crohn’s disease and psoriatic arthritis in adults, and plaque psoriasis in adults and children aged from 6 years.
- J&J reported ~$2.9B in global sales of Stelara in Q2.